Myomo (NYSEAMERICAN:MYO - Get Free Report) is projected to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $9.22 million for the quarter.
Myomo Trading Up 3.0 %
Shares of NYSEAMERICAN MYO traded up $0.14 during trading on Friday, reaching $4.88. The company had a trading volume of 334,749 shares, compared to its average volume of 349,076. Myomo has a 52 week low of $2.76 and a 52 week high of $7.17. The business's 50 day moving average is $4.85. The stock has a market cap of $147.62 million, a PE ratio of -21.22 and a beta of 1.68.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on MYO. HC Wainwright upped their price objective on Myomo from $7.50 to $9.50 and gave the stock a "buy" rating in a report on Wednesday, March 12th. Craig Hallum raised their price target on Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. Ascendiant Capital Markets boosted their price objective on Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Monday, March 17th. Finally, Alliance Global Partners restated a "buy" rating on shares of Myomo in a research report on Tuesday, March 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $9.75.
Check Out Our Latest Stock Report on MYO
Insider Transactions at Myomo
In other Myomo news, insider Micah Mitchell sold 48,000 shares of Myomo stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.16, for a total value of $247,680.00. Following the transaction, the insider now owns 140,572 shares of the company's stock, valued at approximately $725,351.52. The trade was a 25.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Harry Kovelman sold 30,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $5.50, for a total transaction of $165,000.00. Following the completion of the transaction, the insider now owns 97,973 shares of the company's stock, valued at $538,851.50. This trade represents a 23.44 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.54% of the company's stock.
About Myomo
(
Get Free Report)
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.
Read More
Before you consider Myomo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myomo wasn't on the list.
While Myomo currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
